PDS BIOTECHNOLOGY CORP (PDSB)
US70465T1079 - Common Stock
Taking everything into account, PDSB scores 1 out of 10 in our fundamental rating. PDSB was compared to 565 industry peers in the Biotechnology industry. Both the profitability and financial health of PDSB have multiple concerns. PDSB is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
PDSB had negative earnings in the past year.
In the past year PDSB has reported a negative cash flow from operations.
PDSB had negative earnings in each of the past 5 years.
In the past 5 years PDSB always reported negative operating cash flow.
1.2 Ratios
PDSB has a Return On Assets of -67.24%. This is in the lower half of the industry: PDSB underperforms 64.71% of its industry peers.
Looking at the Return On Equity, with a value of -131.57%, PDSB is doing worse than 61.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.24% | ||
| ROE | -131.57% | ||
| ROIC | N/A |
ROA(3y)-50.18%
ROA(5y)-49.37%
ROE(3y)-94.65%
ROE(5y)-79.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PDSB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for PDSB has been increased compared to 1 year ago.
PDSB has more shares outstanding than it did 5 years ago.
PDSB has a worse debt/assets ratio than last year.
2.2 Solvency
PDSB has an Altman-Z score of -3.39. This is a bad value and indicates that PDSB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.39, PDSB is in line with its industry, outperforming 45.63% of the companies in the same industry.
A Debt/Equity ratio of 0.45 indicates that PDSB is not too dependend on debt financing.
PDSB's Debt to Equity ratio of 0.45 is on the low side compared to the rest of the industry. PDSB is outperformed by 74.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.39 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
PDSB has a Current Ratio of 3.84. This indicates that PDSB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.84, PDSB is in line with its industry, outperforming 43.32% of the companies in the same industry.
PDSB has a Quick Ratio of 3.84. This indicates that PDSB is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PDSB (3.84) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.84 | ||
| Quick Ratio | 3.84 |
3. Growth
3.1 Past
PDSB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.58%, which is quite impressive.
EPS 1Y (TTM)31.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
PDSB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.69% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.17%
EPS Next 2Y-1.84%
EPS Next 3Y4.84%
EPS Next 5Y13.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
PDSB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PDSB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.84%
EPS Next 3Y4.84%
5. Dividend
5.1 Amount
No dividends for PDSB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PDS BIOTECHNOLOGY CORP
NASDAQ:PDSB (11/15/2024, 10:01:31 AM)
2.1081
-0.14 (-6.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap77.62M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.24% | ||
| ROE | -131.57% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.84 | ||
| Quick Ratio | 3.84 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)31.58%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y13.17%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y